CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Endpoints News
Original article

Gene editor Scribe starts second-half IPO spree with $129M listing

IPO/OfferingPositive
AI Analysis

Summary

Scribe Therapeutics, a 9-year-old gene editing company co-founded by CRISPR pioneer Jennifer Doudna, priced its IPO at $128.7 million, initiating a wave of biotech IPOs expected in the second half of 2026.

Importance:7/10
Sentiment:
0.60
IPOgene editingCRISPRcapital raising
Related Companies

Read the original article

Published by Endpoints News on July 24, 2026 2:01 AM

Read Original